齐拉西酮和氯丙嗪治疗精神分裂症的对比分析  

Comparative analysis of Ziprasidone and Chlorpromazine in treatment of schizophrenia

作　　者：梅安昌 刘娴[1] 李雪[1] 张西林[2] 李怀滨 夏守翠 吴维[2] 

机构地区：[1]蚌埠市第一人民医院,安徽蚌埠233000 [2]安徽省荣军医院

出　　处：《中国民康医学》2014年第12期14-16,共3页Medical Journal of Chinese People’s Health

摘　　要：目的:通过齐拉西酮与氯丙嗪治疗精神分裂症的疗效和不良反应的对照研究,探讨齐拉西酮治疗精神分裂症的作用。方法:将86例符合ICD-10诊断标准的精神分裂症患者随机分为两组,分别给予齐拉西酮和氯丙嗪系统治疗8周,采用阳性症状和阴性症状量表(PANSS)、副反应量表(TESS)评定患者的临床疗效及不良反应。结果:治疗8周后齐拉西酮组和氯丙嗪组患者的疗效(P>0.05)无显著性差异。齐拉西酮组较氯丙嗪组患者引起的椎体外系反应、胆碱能系统不良反应等发生率低(P<0.05﹚;齐拉西酮对血糖、血脂及体重的影响较氯丙嗪小(P<0.05)。结论:齐拉西酮和氯丙嗪治疗精神分裂症疗效相当,齐拉西酮起效快、不良反应小、耐受性好。Objective：To explore the role of Ziprasidone through a comparative study of the efficacy and side effects of Ziprasi-done and Chlorpromazine in treatment of schizophrenia. Methods：According to the criteria of ICD-10 for schizophrenia, 86 patients were randomly divided into two groups. One group was treated by Ziprasidone for 8 weeks and the other group was treated by Chlor-promazine for 8 weeks. The positive and negative symptom scale （PANSS） and treatment emergent symptom scale （TESS） were used to assess the clinical efficacy and adverse reactions in the study. Results： 8 weeks after the treatment, there was no significant differ-ence in the efficacy between Ziprasidone group and Chlorpromazine group （P〉0. 05）. The incidence rates of extrapyramidal system and cholinergic system responses of Ziprasidone group were lower than those of Chlorpromazine group （P〈0. 05）. The effects of Ziprasidone on blood glucose and blood lipid were less than those of Chlorpromazine （P〈0. 05）. Conclusions： The efficacies of Ziprasidone and Chlorpromazine in the treatment of schizophrenia are similar, however, Ziprasidone has fast effects, good tolerance, and less adverse reactions.

关 键 词：齐拉西酮 氯丙嗪 精神分裂症 

分 类 号：R749.3[医药卫生—神经病学与精神病学]